See more : PT Prodia Widyahusada Tbk (PRDA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of BELLUS Health Inc. (BLU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BELLUS Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tullow Oil plc (TUWOY) Income Statement Analysis – Financial Results
- Warner Bros. Discovery, Inc. (0IBD.L) Income Statement Analysis – Financial Results
- IG Port, Inc. (3791.T) Income Statement Analysis – Financial Results
- Eldeco Housing and Industries Limited (ELDEHSG.NS) Income Statement Analysis – Financial Results
- Tellusgruppen AB (publ) (TELLUS.ST) Income Statement Analysis – Financial Results
BELLUS Health Inc. (BLU)
About BELLUS Health Inc.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00K | 16.00K | 15.00K | 26.79K | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.12M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.74M | 2.91M | 109.80K | 0.00 | 2.25M | 5.52M | 118.83K |
| Cost of Revenue | 3.51B | 2.22B | 1.43B | 994.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -137.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 693.62K | -470.29K | 0.00 | 0.00 | -1.16M | 0.00 | 0.00 |
| Gross Profit | -3.51B | -2.22B | -1.43B | -994.49M | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.26M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.05M | 3.38M | 109.80K | 0.00 | 3.41M | 5.52M | 118.83K |
| Gross Profit Ratio | -21,967,104.08% | -13,887,173.94% | -9,536,119.55% | -3,711,740.75% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 106.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.71% | 116.14% | 100.00% | 0.00% | 151.65% | 100.00% | 100.00% |
| Research & Development | 58.89M | 59.79M | 23.73M | 20.00M | 5.28M | 2.87M | 1.13M | 931.76K | 1.46M | 1.19M | 998.16K | 1.29M | 7.05M | 10.04M | 23.60M | 55.45M | 49.54M | 40.61M | 24.42M | 5.71M | 8.03M | 6.56M | 3.19M |
| General & Administrative | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 0.00 | 7.69M | 8.57M | 11.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 611.90K | 3.71M | 6.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 3.47M | 8.30M | 12.28M | 18.45M | 15.17M | 14.67M | 23.25M | 18.29M | 5.75M | 2.44M | 396.43K | 1.02M |
| Other Expenses | -491.00K | -754.00K | -507.00K | -543.53K | -479.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 653.38K | 5.34M | -5.05M | 13.11M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 65.73M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Cost & Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 66.42M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Interest Income | 5.08M | 233.00K | 1.05M | 1.16M | 265.78K | 63.62K | 74.40K | 104.49K | 170.56K | 189.71K | 137.71K | 105.78K | 151.98K | 102.00K | 907.00K | 0.00 | 2.36M | 2.08M | 0.00 | 520.42K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 78.00K | 55.00K | 39.00K | 22.97K | 3.67K | 8.75K | 8.18K | 7.93K | 89.59K | 133.36K | 220.14K | 333.01K | 526.92K | 324.00K | 271.00K | 0.00 | 151.45K | 461.68K | 0.00 | 46.37K | 232.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 426.00K | 1.22M | 1.28M | 325.25K | 63.62K | 49.10K | 104.49K | 345.43K | 658.36K | -17.49M | 45.05K | 1.47M | 693.00K | 1.88M | 399.00K | 335.82K | 2.60M | 1.70M | 497.67K | 585.56K | 278.82K | 224.15K |
| EBITDA | -72.76M | -72.86M | -31.72M | -24.82M | -6.95M | -4.46M | -1.51M | 28.10K | -1.78M | -2.43M | -21.12M | -1.71M | -13.22M | -7.21M | -46.07M | -66.97M | -62.16M | -60.94M | -42.60M | -11.46M | -8.22M | -1.44M | -4.09M |
| EBITDA Ratio | -454,768.75% | -455,362.50% | -211,453.33% | -92,637.22% | -27,038.13% | -3,396.99% | -107.29% | 0.97% | -87.04% | -114.72% | -914.36% | -56.95% | -549.21% | 6,215.52% | -7,888.36% | -4,443.66% | -2,266.69% | -2,091.58% | -38,800.14% | 0.00% | -365.10% | -26.07% | -3,440.36% |
| Operating Income | -77.88M | -73.28M | -32.94M | -26.10M | -7.27M | -4.52M | -1.56M | -76.39K | -2.13M | -3.09M | -3.64M | -1.76M | -14.69M | -21.12M | -45.66M | -68.66M | -63.68M | -63.69M | -44.30M | -11.95M | -8.81M | -1.72M | -4.31M |
| Operating Income Ratio | -486,768.75% | -458,025.00% | -219,613.33% | -97,431.66% | -28,303.89% | -3,445.47% | -110.78% | -2.63% | -103.91% | -145.79% | -157.40% | -58.45% | -610.09% | 18,204.31% | -7,817.64% | -4,555.81% | -2,321.87% | -2,185.81% | -40,350.15% | 0.00% | -391.10% | -31.13% | -3,629.00% |
| Total Other Income/Expenses | 1.86M | 1.86M | 1.19M | -280.19K | 603.51K | 3.08M | -86.30K | 348.78K | 389.37K | 2.18M | -9.60M | 5.34M | -5.05M | 12.89M | -2.57M | -12.42M | -999.45K | 1.38M | 714.67K | -1.35M | 74.51K | 0.00 | 316.65K |
| Income Before Tax | -76.02M | -71.42M | -31.76M | -26.39M | -6.67M | -1.44M | -1.65M | 272.40K | -1.74M | -911.93K | -13.24M | 3.58M | -19.73M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -13.30M | -8.73M | 0.00 | -4.00M |
| Income Before Tax Ratio | -475,125.00% | -446,393.75% | -211,713.33% | -98,477.40% | -25,955.23% | -1,098.79% | -116.90% | 9.39% | -84.89% | -43.04% | -573.11% | 119.24% | -819.68% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -387.79% | 0.00% | -3,362.52% |
| Income Tax Expense | 60.00K | -199.00K | 39.00K | 22.97K | -607.18K | 48.51K | 11.16K | -19.46K | -42.21K | -617.97K | 18.44M | 227.23K | 374.94K | 13.44M | 1.32M | -1.94M | -1.50M | -2.04M | -626.83K | -365.56K | 152.98K | 58.14K | -227.53K |
| Net Income | -76.08M | -71.22M | -31.80M | -26.41M | -6.06M | -1.49M | -1.61M | 145.57K | -1.66M | -818.96K | -13.32M | 3.35M | -20.11M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -12.93M | -8.89M | -1.78M | -3.77M |
| Net Income Ratio | -475,500.00% | -445,150.00% | -211,973.33% | -98,563.12% | -23,592.29% | -1,135.76% | -114.05% | 5.02% | -81.27% | -38.65% | -576.81% | 111.68% | -835.26% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -394.58% | -32.18% | -3,171.04% |
| EPS | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | 1.38 | -10.28 | -6.34 | -105.15 | -198.86 | -181.01 | -196.26 | -156.38 | -52.10 | -53.29 | -11.00 | -32.16 |
| EPS Diluted | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | -0.67 | -10.28 | -6.30 | -105.15 | -198.86 | -181.01 | -187.15 | -137.04 | -44.64 | -49.86 | -11.00 | -32.16 |
| Weighted Avg Shares Out | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 2.47M | 1.96M | 1.30M | 458.62K | 407.69K | 357.31K | 317.48K | 278.73K | 248.27K | 166.73K | 161.45K | 117.17K |
| Weighted Avg Shares Out (Dil) | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 6.04M | 1.96M | 1.31M | 458.62K | 407.69K | 357.31K | 332.93K | 318.06K | 289.73K | 178.21K | 161.45K | 117.17K |
BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR). The post NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today appeared first on InvestorPlace.
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. The post BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today appeared first...
Pharma Stock Hits Annual High on Study Results
The shares of Bellus Health Inc (NASDAQ:BLU) are soaring today, up 63% to trade at $9.13 at last check, after the Canada-based drug name announced positive results from a mid-stage study of its cough therapy drug candidate, BLU-5937.
Biotech Penny Stocks To Buy After BLU Stock Explodes? 3 To Watch
3 biotech penny stocks to watch after Bellus Health (BLU) skyrockets. The post Biotech Penny Stocks To Buy After BLU Stock Explodes?
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg...
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg...
Is the Options Market Predicting a Spike in BELLUS Health (BLU) Stock?
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.
Bellus Health (BLU) Reports Q3 Loss
Bellus (BLU) delivered earnings and revenue surprises of -20.83% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today reported its financial and operating results for the...
Source: https://incomestatements.info
Category: Stock Reports